Purple Biotech Receives Extension From Listing Qualifications Department Of Nasdaq To Regain Compliance With Minimum $1.00 Bid Price Requirement
Portfolio Pulse from Benzinga Newsdesk
Purple Biotech has received an extension from the Nasdaq Listing Qualifications Department to regain compliance with the minimum $1.00 bid price requirement.
July 25, 2024 | 11:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Purple Biotech has been granted an extension by Nasdaq to meet the $1.00 minimum bid price requirement, providing the company more time to avoid delisting.
The extension from Nasdaq reduces the immediate risk of delisting for Purple Biotech, which is positive news for the stock. Investors may see this as a temporary relief, potentially leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100